Findings

What do systematic reviews say?

6 questions · 6 findings · 1 reviews

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 1 · 16.7%Low 3 · 50%Moderate 2 · 33.3%High 0 · 0%

Clinical relapse · people with surgically‐induced remission in Crohn's disease

5‐ASA showed no clear difference in clinical relapse compared with no treatment (low certainty).

1 finding from 1 review

Clinical relapse · people with surgically‐induced remission in Crohn's disease

High dose 5‐ASA showed no clear difference in clinical relapse compared with low dose 5‐ASA (moderate certainty).

1 finding from 1 review

Oral 5‐aminosalicylic acid for maintenance of surgically‐induced remission in Crohn's disease 2019 · Cochrane Headline outcomes only
RR 0.65 [0.38, 1.13]
1 study · 206 participants
Moderate

Clinical relapse · people with surgically‐induced remission in Crohn's disease

5‐ASA showed no clear difference in clinical relapse compared with purine antimetabolites (low certainty).

1 finding from 1 review

Clinical relapse · people with surgically‐induced remission in Crohn's disease

It is very uncertain whether 5‐ASAs changes clinical relapse compared with anti TNF‐ɑ (very low certainty).

1 finding from 1 review

Clinical relapse · people with surgically‐induced remission in Crohn's disease

Sulphasalazine showed no clear difference in clinical relapse compared with placebo (low certainty).

1 finding from 1 review

Clinical relapse · people with surgically‐induced remission in Crohn's disease

5‐ASAs probably leads to lower clinical relapse compared with placebo (moderate certainty).

1 finding from 1 review

Oral 5‐aminosalicylic acid for maintenance of surgically‐induced remission in Crohn's disease 2019 · Cochrane Headline outcomes only
RR 0.83 [0.72, 0.96]
5 studies · 730 participants
Moderate